Retatrutide: The Triple Agonist That's Rewriting the Rules of Metabolic Health Research

Introduction: Beyond the GLP-1 Era

The emergence of GLP-1 receptor agonists — semaglutide and tirzepatide — fundamentally changed what medicine believed was possible in obesity pharmacotherapy. For the first time, compounds were producing body mass reduction outcomes previously only achievable through bariatric surgery.

Then Retatrutide entered Phase 2 trials, and the bar moved again.

Retatrutide (LY3437943), developed by Eli Lilly, is a triple hormone receptor agonist that simultaneously activates three distinct metabolic pathways through a single weekly injection. Phase 3 TRIUMPH trial results show body mass reduction approaching 30% of total body weight — outcomes that, until recently, were the exclusive domain of surgical intervention.

Part 1: Three Pathways, One Molecule

1.1 GLP-1 Receptor Agonism — Appetite and Satiety

Glucagon-Like Peptide-1 (GLP-1) is a naturally occurring incretin hormone released from the gut after eating. It signals satiety to the brain, slows gastric emptying, and stimulates insulin secretion in a glucose-dependent manner. Retatrutide activates the GLP-1 receptor, contributing appetite suppression and delayed gastric emptying — the foundation of all modern metabolic pharmacotherapy.

1.2 GIP Receptor Agonism — Metabolic Efficiency

Glucose-Dependent Insulinotropic Polypeptide (GIP) receptors are found in the pancreas, adipose tissue, bone, and brain. GIP agonism enhances the effects of GLP-1, may improve lipid handling in adipose tissue, reduce gastrointestinal side effects, and may support bone health and lean muscle preservation during body recomposition.

Tirzepatide was the first approved drug to combine GLP-1 and GIP agonism. A 2025 NEJM head-to-head trial confirmed tirzepatide's superiority over semaglutide, with 32% of tirzepatide patients achieving ≥25% body mass reduction versus 16% on semaglutide.

1.3 Glucagon Receptor Agonism — The Energy Expenditure Advantage

This is where retatrutide differentiates itself most clearly. Glucagon receptor agonism promotes lipolysis (fat breakdown), increases hepatic fat oxidation, and — most importantly — increases resting energy expenditure. The body burns more calories at rest.

This is the mechanism that neither semaglutide nor tirzepatide possess. A 2024 ScienceDirect review confirmed: "In preclinical models, retatrutide treatment reduced food intake and also increased energy expenditure, an effect attributable to glucagon receptor agonism."

In simple terms: semaglutide tells you to eat less. Retatrutide tells you to eat less, makes you feel fuller for longer, and simultaneously turns up your metabolic furnace.

Part 2: The Clinical Evidence

2.1 Phase 2 NEJM Trial — Setting the Benchmark

Published in The New England Journal of Medicine in 2023, the Phase 2 results were striking:

• 12mg dose: 24.2% mean body weight reduction at 48 weeks
• 8mg dose: 22.8% body mass reduction at 48 weeks
• 92% of participants achieved ≥5% body mass reduction
• 75% achieved ≥10% body mass reduction
• 60% achieved ≥15% body mass reduction

For context: semaglutide Phase 3 produced ~14.9% body mass reduction. Tirzepatide Phase 3 produced ~20.9%. Retatrutide's Phase 2 results already exceeded the Phase 3 ceiling of its predecessors.

2.2 Phase 3 TRIUMPH Trials — Surgery-Level Outcomes

TRIUMPH-1 (obesity, 80 weeks, 12mg):

• Mean body weight reduction: 28.3% — average loss of 70.3 lbs (32kg)
• 45.3% of participants achieved ≥30% body mass reduction
• At 104 weeks: 30.3% body mass reduction — matching bariatric surgery outcomes

TRIUMPH-4 (obesity with knee osteoarthritis, 68 weeks, 12mg):

• Mean body weight reduction: 28.7%
• Significant reduction in knee pain scores
• Demonstrates meaningful functional benefits beyond body weight

Part 3: Safety Profile

The primary adverse effects are gastrointestinal — nausea, vomiting, diarrhoea — most common during dose escalation, generally transient and resolving as the body adapts. No unexpected safety signals were reported across Phase 2 and 3 trials. No hypoglycaemia risk, consistent with the glucose-dependent mechanism.

A dedicated cardiovascular outcomes trial (CVOT) is underway. Current data has not identified cardiovascular safety concerns.

Part 4: Retatrutide in Context

vs Semaglutide

Semaglutide operates through GLP-1 agonism alone, producing ~14-15% body mass reduction at therapeutic doses. Retatrutide produces approximately double that. The additional GIP and glucagon components — particularly the energy expenditure effect — appear responsible for the gap.

vs Tirzepatide

Tirzepatide produces ~20-21% body mass reduction. Retatrutide adds glucagon receptor agonism that tirzepatide lacks, producing another meaningful step up in efficacy. A 2025 Nature paper concluded retatrutide demonstrates "superior efficacy" compared to both semaglutide and tirzepatide.

vs Bariatric Surgery

Roux-en-Y gastric bypass produces 25-35% total body mass reduction. Retatrutide's Phase 3 data — 28-30% at 80-104 weeks — now sits within that surgical range, without the risks, cost, recovery time, or permanence of surgical intervention. Pharmacological research into elevated adiposity may be capable of matching surgical outcomes for a meaningful proportion of subjects.

Conclusion

Retatrutide represents the clearest example yet that incretin-based pharmacology has not reached its ceiling. The TRIUMPH trials have demonstrated that a weekly injection can produce surgical-level body composition outcomes — the step-change in body composition outcomes that retatrutide produces is reshaping research around metabolic health, elevated adiposity, and incretin pharmacology. Phase 3 publications are expected through 2025-2026, with regulatory submissions to the FDA anticipated.

References

1. Jastreboff, A.M. et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. doi: 10.1056/NEJMoa2301972.
2. Katsi, V. et al. (2025). Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules, 15(6), 796. PMC12190491.
3. Eli Lilly & Company (2025). TRIUMPH-1 Phase 3 Trial Results.
4. Eli Lilly & Company (2025). TRIUMPH-4 Phase 3 Trial Results.
5. Frías, J.P. et al. (2025). Tirzepatide as Compared with Semaglutide. New England Journal of Medicine. PMID: 40353578.
6. Ludvik, B. et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. The Lancet.